/Lilly(Eli)%20%26%20Co%20logo%20on%20building-by%20Michael%20Vi%20via%20Shutterstock.jpg)
Eli Lilly and Company (LLY) is a global leader in healthcare innovation, specializing in discovering, developing, and delivering life-changing medicines to address some of the world's most pressing medical needs. With a market cap of $759.4 billion, Eli Lilly operates across diverse therapeutic areas, providing cutting-edge solutions in oncology, diabetes, immunology, and neuroscience. The Indianapolis, Indiana-based company is set to release its Q4 earnings on Tuesday, Feb. 4.
Ahead of the event, analysts expect Eli Lilly to report a profit of $5.43 per share, up 118.1% from $2.49 per share reported in the year-ago quarter. The company beat the consensus estimates in three of the last four quarters while missing on another occasion. Its EPS of $1.18 for the last reported quarter missed the consensus estimates by 22.4%. Eli Lilly's Q3 miss was driven by inventory decreases at wholesalers, impacting Zepbound and Mounjaro sales despite strong year-over-year growth.
